FDA schedules advisory committee meeting for BrainStorm's NurOwn BLA on Sept 27, 2023

BRAINSTORM CELL THERAPEUTICS INC.

FDA Cellular, Tissue and Gene Therapies Advisory Committee to review NurOwn BLA for ALS on September 27, 2023.
PDUFA target action date set for December 8, 2023.
Company states confidence in data supporting regulatory approval and commitment to ALS community.
BrainStorm notes FDA regulatory flexibility and ongoing work with ALS experts on rigorous clinical study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.